Novel Perspectives of ctDNA-Based Liquid Biopsy in Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 182
Special Issue Editor
2. Wisconsin Center for NanoBioSystems (WisCNano), University of Wisconsin-Madison, Madison, WI 53705, USA
3. Department of Biological Sciences and Bioengineering, Inha University, Incheon 22212, Republic of Korea
4. Industry-Academia Interactive R&E Center for Bioprocess Innovation, Inha University, Incheon 22212, Republic of Korea
Interests: circulating tumor cells (CTCs); exosomes; cell-free DNA (cfDNA); nanoparticle-based drug delivery
Special Issue Information
Dear Colleagues,
Fragmented DNA in body fluids originating from tumor cells, also known as circulating tumor DNA (ctDNA), has drawn considerable scientific and clinical attention as a biomarker for various cancers. ctDNA testing examines a patient’s body fluid (mainly blood) to detect DNA fragments from cancer cells. Recent advances in next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies have led ctDNA to become the predominant biomarker of liquid biopsies to understand the tumor status of a patient and explore the genetic landscape of cancer. Specifically, accumulating evidence has revealed that the detection of cancer-specific gene mutation or amplification in body fluid is strongly associated with a poor prognosis.
In this Special Issue on “Novel Perspectives of ctDNA-Based Liquid biopsy in Oncology”, we aim to cover all aspects of the sciences, processes, and engineering techniques related to the development and analysis of liquid biopsy systems using ctDNA as a tumor biomarker. This issue will also highlight clinical trials of ctDNA in diagnosing and characterizing tumor, as well as monitoring and estimating prognoses.
Dr. Jiyoon Bu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- circulating tumor DNA (ctDNA)
- cell-free DNA (cfDNA)
- liquid biopsy
- tumor biomarker
- next generation gene sequencing (NGS)
- tumor diagnosis
